Stock ALZN ALZAMEND NEURO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Alzamend Neuro, Inc.

Equities

ALZN

US02262M4078

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:00 01/05/2024 BST 		5-day change 1st Jan Change
0.718 USD +0.98% Intraday chart for Alzamend Neuro, Inc. -1.05% -19.33%
03-25 Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
01-31 Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC CI

Business Summary

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's through a royalty-bearing exclusive worldwide license from the Licensor.

Number of employees: 6

Managers

Managers TitleAgeSince
Stephan Jackman CEO
 Chief Executive Officer 48 19/11/18
David Katzoff DFI
 Director of Finance/CFO 63 31/10/19
William Horne CHM
 Chairman 55 31/05/16
Henry Nisser BRD
 Director/Board Member 56 30/04/19
James Turner LAW
 General Counsel 49 31/03/21
Kenneth Cragun PRN
 Corporate Officer/Principal 63 30/09/18

Members of the board

Members of the board TitleAgeSince
Mark Gustafson BRD
 Director/Board Member 64 31/05/21
Todd Ault FOU
 Founder 54 24/02/16
William Horne CHM
 Chairman 55 31/05/16
Jeffrey Oram BRD
 Director/Board Member 56 31/05/21
Henry Nisser BRD
 Director/Board Member 56 30/04/19
Lynne McGrath BRD
 Director/Board Member 69 31/05/21
Stephan Jackman CEO
 Chief Executive Officer 48 19/11/18
Andrew Woo BRD
 Director/Board Member 61 31/05/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 6,866,846 4,831,824 ( 70.36 %) 0 70.36 %

Shareholders

NameEquities%Valuation
Todd Ault
17.02 %
1,168,560 17.02 % 1 M $
AULT ALLIANCE, INC.
11.24 %
771,699 11.24 % 771 699 $
Truist Bank
2.247 %
154,327 2.247 % 154 327 $
Vanguard Group, Inc. (Subfiler)
1.144 %
78,545 1.144 % 78 545 $
William Horne
0.9708 %
66,666 0.9708 % 66 666 $
Geode Capital Management LLC
0.7630 %
52,397 0.7630 % 52 397 $
BlackRock Institutional Trust Co. NA
0.5787 %
39,740 0.5787 % 39 740 $
HRT Financial LLC
0.2447 %
16,806 0.2447 % 16 806 $
RFG Advisory LLC
0.2427 %
16,666 0.2427 % 16 666 $
Renaissance Technologies LLC
0.1484 %
10,190 0.1484 % 10 190 $
NameEquities%Valuation
AULT ALLIANCE, INC.
0.1627 %
1,220 0.1627 % 1 220 $

Company contact information

Alzamend Neuro, Inc.

3480 Peachtree Road NE Suite 103

30326, Atlanta

+844 722 6333

http://www.alzamend.com
address Alzamend Neuro, Inc.(ALZN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.711 USD
Average target price
21 USD
Spread / Average Target
+2,853.59%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ALZAMEND NEURO, INC. Stock Alzamend Neuro, Inc.
-19.33% 4.88M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.19B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.57% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 10.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 9.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALZN Stock
  4. Company Alzamend Neuro, Inc.